| Literature DB >> 35172092 |
Hyun Woo Kim1, Hyejung Chang2.
Abstract
OBJECTIVE: E-detailing methods have steadily evolved toward more contactless and interactive channels, which have received considerable attention during the coronavirus disease 2019 (COVID-19) crisis. Based on the technology acceptance model, this study attempted to identify medical representatives' perceptions and attitudes towards individual innovativeness that affected users' intentions to adopt new e-detailing devices utilizing information and communication technology.Entities:
Keywords: Diffusion of Innovation; Drug Industry; Marketing; Mediation Analysis; Mobile Applications
Year: 2022 PMID: 35172092 PMCID: PMC8850167 DOI: 10.4258/hir.2022.28.1.68
Source DB: PubMed Journal: Healthc Inform Res ISSN: 2093-3681
Figure 1Theoretical framework.
Results of principal component analysis on PU and PEOU with respect to remote e-detailing technology by platforms
| Item | Desktop PC platform | Mobile platform | ||||
|---|---|---|---|---|---|---|
| PU | PEOU | Uniqueness | PU | PEOU | Uniqueness | |
| Using remote e-detailing will enhance my effectiveness on the job. | 0.64 | - | 0.42 | 0.78 | - | 0.36 |
| Using remote e-detailing will reduce the time I spend on unproductive activities. | 0.77 | - | 0.43 | 0.82 | - | 0.40 |
| Doctors will actually prefer remote e-detailing over direct visits. | 0.83 | - | 0.34 | 0.83 | - | 0.34 |
| Detailing will be more effective than direct visiting. | 0.81 | - | 0.40 | 0.79 | - | 0.39 |
| Using remote e-detailing will allow me to accomplish more than would otherwise be possible. | 0.73 | - | 0.40 | 0.65 | - | 0.39 |
| I am familiar with how remote e-detailing works. | - | 0.67 | 0.40 | - | 0.67 | 0.47 |
| It will be easy for me to learn how to perform tasks using remote e-detailing. - | 0.91 | 0.24 | - | 0.91 | 0.25 | |
| Using remote e-detailing will be more convenient than making direct visits. | - | 0.66 | 0.57 | - | 0.68 | 0.50 |
| Eigenvalue | 3.71 | 1.09 | - | 3.70 | 1.21 | - |
| % variance explained | 0.46 | 0.14 | - | 0.46 | 0.15 | - |
PU: perceived usefulness, PEOU: perceived ease of use.
Results of principal component analysis on personal innovativeness
| Item | Factor loading | Uniqueness |
|---|---|---|
| I am always interested in novel technologies. | 0.84 | 0.29 |
| I like to experiment with new technologies. | 0.89 | 0.20 |
| In general, I have no difficulty trying out new technologies. | 0.87 | 0.25 |
| I am familiar with novel technologies. | 0.81 | 0.34 |
| Among my peers, I am usually the first to try out new technologies. | 0.86 | 0.26 |
| Eigenvalue | 3.72 | - |
| % variance explained | 0.74 | - |
Descriptive statistics
| Covariate | Value (min–max) |
|---|---|
| Variables of interest | |
| UA (PC) | 2.74 ± 1.10 (1–5) |
| PU (PC) | 0 ± 1.00 (−2.11–2.10) |
| PEOU (PC) | 0 ± 1.00 (−2.99–2.61) |
| UA (Mobile) | 2.71 ± 1.06 (1–5) |
| PU (Mobile) | 0 ± 1.00 (−2.17–2.31) |
| PEOU (Mobile) | 0 ± 1.00 (−2.83–2.61) |
| Personal innovativeness | 0 ± 1.00 (−3.23–2.06) |
| Gender | |
| Man | 0.61 (0–1) |
| Woman | 0.39 (0–1) |
| Education | |
| Graduated college/university | 0.89 (0–1) |
| Hold postgraduate degree | 0.11 (0–1) |
| Position | |
| Staff/chief | 0.63 (0–1) |
| Assistant manager | 0.25 (0–1) |
| Manager/deputy general manager | 0.12 (0–1) |
| Working context | |
| Number of doctors in charge | 12.32 ± 2.78 (2–25) |
| Number of medicines in charge | 2.18 ± 1.37 (1–6) |
| Company | |
| Pfizer Korea | 0.63 (0–1) |
| Hanmi Pharmaceutical | 0.19 (0–1) |
| Jeil Pharmaceutical | 0.18 (0–1) |
Values are presented as mean ± standard deviation for continuous variables and proportion for categorical variables, respectively.
PEOU: perceived ease of use, PU: perceived usefulness, UA: user acceptance.
Structural model estimates of PU and UA of remote e-detailing technology regressed on selected variables by platform types
| Covariate | Model 1 (Desktop PC platform) | Model 2 (Mobile platform) | ||||||
|---|---|---|---|---|---|---|---|---|
| Outcome: PU | Outcome: UA | Outcome: PU | Outcome: UA | |||||
| B | SE | B | SE | B | SE | B | SE | |
| Variables of interest | ||||||||
| PEOU | 0.44 | 0.06 | 0.18 | 0.06 | 0.38 | 0.06 | 0.21 | 0.06 |
| Personal innovativeness | −0.02 | 0.07 | 0.04 | 0.06 | −0.01 | 0.07 | 0.16 | 0.05 |
| PU | 0.68 | 0.05 | 0.66 | 0.06 | ||||
| PU × personal innovativeness | 0.13 | 0.04 | 0.06 | 0.04 | ||||
| Gender | ||||||||
| Man | (Reference category) | (Reference category) | ||||||
| Woman | 0.38 | 0.13 | 0.27 | 0.11 | 0.37 | 0.12 | 0.11 | 0.10 |
| Education | ||||||||
| Graduated college/university | (Reference category) | (Reference category) | ||||||
| Hold postgraduate degree | 0.38 | 0.15 | −0.08 | 0.17 | 0.41 | 0.18 | −0.16 | 0.13 |
| Position | ||||||||
| Staff/chief | (Reference category) | (Reference category) | ||||||
| Assistant manager | 0.11 | 0.16 | −0.14 | 0.12 | 0.02 | 0.15 | −0.10 | 0.11 |
| Manager/deputy general manager | 0.40 | 0.16 | 0.14 | 0.14 | 0.52 | 0.17 | 0.17 | 0.14 |
| Working context | ||||||||
| Number of doctors in charge | −0.03 | 0.02 | −0.02 | 0.02 | −0.02 | 0.02 | 0.00 | 0.02 |
| Number of medicines in charge | 0.04 | 0.05 | −0.02 | 0.03 | −0.01 | 0.05 | −0.02 | 0.04 |
| Constant | −0.03 | 0.25 | 2.88 | 0.29 | 0.03 | 0.27 | 2.70 | 0.22 |
| R2 | 0.31 | 0.63 | 0.29 | 0.63 | ||||
The number of observation is 221. Robust standard errors in parentheses. PEOU: perceived ease of use, PU: perceived usefulness, UA: user acceptance.
p < 0.05,
p < 0.01,
p < 0.001.
Summary of direct, indirect, and total effects of PEOU on UA, by platform types
| Causal path | Model | Direct effect | Indirect effect | Total effect | % mediated |
|---|---|---|---|---|---|
| PEOU → PU → UA (Desktop PC platform) | Estimated without controls | 0.19 [0.09, 0.32] | 0.35 [0.26, 0.44] | 0.54 [0.43, 0.66] | 64.3 |
| Estimated with controls, without moderated mediator | 0.17 [0.05, 0.29] | 0.31 [0.22, 0.43] | 0.48 [0.34, 0.62] | 65.3 | |
| Estimated with controls and moderated mediator | 0.18 [0.07, 0.32] | 0.30 [0.21, 0.40] | 0.48 [0.35, 0.64] | 61.9 | |
| PEOU → PU → UA (Mobile platform) | Estimated without controls | 0.26 [0.15, 0.29] | 0.30 [0.28, 0.36] | 0.56 [0.43, 0.62] | 54.2 |
| Estimated with controls, without moderated mediator | 0.20 [0.09, 0.31] | 0.26 [0.17, 0.37] | 0.46 [0.34, 0.58] | 56.2 | |
| Estimated with controls and moderated mediator | 0.21 [0.10, 0.32] | 0.25 [0.16, 0.36] | 0.46 [0.33, 0.57] | 54.8 |
Bias-corrected confidence interval in brackets.
PEOU: perceived ease of use, PU: perceived usefulness, UA: user acceptance.